A panel discussion with:
Bringing cell & gene therapies to market is no easy feat. The many technicalities involved in running trials, scaling manufacturing capabilities, market access and launch drives up end-to-end costs, meaning patients are often faced with a complex, long and expensive road to treatment.
With the aim to bring CGT’s to as many patients as possible, panellists discuss the early-commercial planning factors facing CGT companies today and tried-and-tested solutions.
In partnership with
Inizio unlocks the value of your healthcare innovation by connecting best-in-class strategic, analytic, and creative capabilities. By bridging our scientific knowledge, market intelligence, actionable data, cutting-edge technology, and creative execution, Inizio is by your side to help you confidently navigate the complex asset lifecycle, rising to any challenges together.